
FRANCE BIRD FLU
Antibiotics, the PASTEUR Act, and a Race Against Time
Published Dec. 28, 2022 • Read time: 5m
If you’re familiar with the name “Pasteur,” it might very well be because an early science fair project or a chapter in middle school biology introduced you to the field of bacteriology. Question number 5 on the final might have been, “Name the husband-and-wife team whose transformational work ushered in a new era of understanding of bacteria and the diseases they cause.” And you’d have answered – because of course, you studied – “Louis and Marie Pasteur.”
Drawing on that familiarity, members of Congress have introduced a legislative proposal with a tortured but nevertheless memorable acronym: PASTEUR (Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) Act. The bill, sponsored by Democratic Sen. Michael Bennet of Colorado and co-sponsored by a bi-partisan group of more than 60, would create a subscription-style payment model – referred to by some as a “medical Netflix” model – by which the government would pay drug manufacturers billions of dollars up-front for unlimited access to new antibiotics over a specified period of time.
New drugs are expensive to develop, produce, and shepherd through the regulatory process, and pharmaceutical firms attempt to recoup their investment by charging the government and insurance companies commensurately high prices. But the longer the process and the more expensive the drug, the greater the chance that new or evolving pathogens will have time to outrun the cures.
For several decades, medical and global public health experts have warned that our toolbox of effective antibiotics is shrinking fast, as pathogens mutate to evade all attempts to thwart them. The UN has estimated that by 2050, microbes that are able to ignore our best pharmaceutical efforts could kill 10 million people every year – becoming the world’s leading cause of death.
Gavin Newsom's Misguided Redistricting Initiative
A Warning Against the Overuse of Sanctions
Open The Books on the California State Checkbook
Senate Passes Bill Addressing Heroin, Opioid Crisis
I came perilously close to being one of the unlucky ones.
Degenerative osteoarthritis made it necessary for me to have my hips replaced in my 40s, and a few years later a simple fall, complicated by the joint implant, fractured my femur. After a stint in traction and the opinions of several orthopedic surgeons, the fracture was repaired with a dizzying combination of wires, screws, and clamps. All seemed well, until a few months later when I developed an infection in the artificial joint. The diagnosis was grim: I needed to give permission for what is referred to as a two-stage hip revision. If I declined, there was an 80% chance I would lose the whole leg. Or worse.
So I signed my name on a form that authorized this procedure, described by a leading orthopedic journal:
Two stage revision is a technique in which the in situ prosthesis is removed, a thorough debridement of bone and soft tissue is performed, an interval spacer is inserted, antibiotics administered. The 2nd stage of definitive reconstruction is performed once the infection is deemed to have resolved. The interval between stages can range from 6 weeks to several months.
In my case, the interval – from the date my hip was removed until “the infection is deemed resolved” – was 123 days. During this time I was confined to a rented hospital bed in my home, treated with a cocktail of powerful antibiotics through a PICC line in my neck (which itself became infected twice), and had my blood levels checked by a home health care professional three times a week.
The main antibiotic assigned with the task of shutting down my infection was Rifampin, one of the last of a line of drugs still somewhat effective against tuberculosis and a few other diseases that are becoming harder and harder to defeat. In my case the treatment was brutal: I threw up every single day. I begged my doctors to try another drug, but when they did, the infection went in the wrong direction. One particularly curt infectious disease doctor fixed his gaze on me and said, “Look, we’re talking about your life here. Up to you. We don’t have anything else.” I chose to go back on the Rifampin and keep throwing up.
Drug resistance, for me, is not theoretical. The microbes that threatened to kill me had at least partially evaded a powerful drug that, 10 years earlier, would have worked in less than half the time. And there were other drugs that might have worked then, too, but are now relatively useless against potentially fatal bacteria. It’s essential that drug researchers and manufacturers sprint to keep one step ahead of these pathogens – and then prepare for the marathon of staying ahead.
Some policy makers and researchers have expressed concerns about possible unintended consequences of the proposed legislation, and their reservations concern me as well. I don’t claim to have the answers. But it’s clear that we can’t continue kicking the can of drug-resistant pathogens down the road until there is no more road.
A century and a half after Louis and Marie Pasteur pioneered the field of microbiology, perhaps we need a new model, named after them and honoring their work – one that could give us the next set of tools in the fight.

Democrats Won the Midterms. Common Sense Won, Too
Jordanne Kemper • RealClearPolitics
The 120th Congress Shapes Up
Carolina Lumetta • RealClearPolitics
Flooding GOP Primaries With Democrats
Robert Natelson • RealClearPolitics
Washington Keeps Rewarding Oracle—Veterans Keep Paying the Price
Darin Gaub • RealClearPolitics
The Seeds of Unrestricted Warfare
John Teichert • RealClearPolitics
The Primary System Is Losing the Next Generation
Sean Trende • RealClearPolitics
RCP Today
Top stories on RealClearPolitics
The Takeaway
Polling intelligence and analysis delivered to your inbox
World News
Featuring the latest world news
Policy
Featuring the latest policy news
Support Our Mission
As part of RealClearPolitics, authors aim to provide balanced, non-partisan analysis by presenting top reporting and commentary from all sides of the political spectrum.
Trusted by policymakers and citizens alike since 2000
